Estimating the budget impact of introducing dostarlimab as first line in treating endometrial cancer in Saudi Arabia.
Introducing dostarlimab plus CP for endometrial cancer treatment may be budget neutral, but clinical outcomes and efficacy data are not provided.
Where it sits
this study against the rest of the mgf (mechano growth factor) corpusSummary and findings
The budget impact of introducing dostarlimab plus carboplatin-paclitaxel (CP) as a first-line treatment for endometrial cancer in Saudi Arabia was evaluated. The analysis estimated that 58 patients would receive the treatment in the first year, increasing to 242 by the third year. The total cumulative budget impact was -$1,650,171 over three years.
Abstract
<h4>Objective</h4>The budget impact of introducing dostarlimab plus carboplatin-paclitaxel (CP) as a first-line treatment option for primary advanced or recurrent endometrial cancer (EC) in Saudi Arabia was evaluated from the perspective of the Saudi national payer.<h4>Methods</h4>The budget impact model (BIM) utilized epidemiological, clinical, and cost and resource use inputs to evaluate the total costs associated with a market scenario without dostarlimab versus a market scenario with dostarlimab over a three-year time horizon (2026-2028). Currently available comparator treatments in Saudi Arabia were evaluated based on associated market share and relevance as comparable treatment regimens to dostarlimab plus CP. A one-way sensitivity analysis was performed to identify the sensitivity of the BIM to changes in input parameters.<h4>Results</h4>Out of 250 eligible patients, 58 were estimated to receive dostarlimab plus CP as a first-line EC treatment during its first year on the market, increasing to 242 out of 569 eligible patients in the third year. The resulting annual budget impact was -$326,607 in the first year and -$668,830 in the third year of market availability, with a total cumulative budget impact of -$1,650,171 over the three-year time horizon. The mean annual budget impact per patient treated with dostarlimab plus CP was -$4,388.57, a decrease of -1.84% compared with the scenario without dostarlimab.<h4>Conclusions</h4>The introduction of dostarlimab plus CP to healthcare settings for first-line treatment of primary advanced and recurrent EC was found to be budget neutral in this model, with lower treatment acquisition costs and decreased second-line subsequent treatment costs compared with the other currently available treatment options.
Background
This paper addresses the economic implications of introducing dostarlimab plus carboplatin-paclitaxel (CP) for treating advanced or recurrent endometrial cancer in Saudi Arabia. Prior to this study, the cost-effectiveness of dostarlimab in this context was not well established, making this analysis relevant for healthcare decision-makers. Understanding the budget impact is crucial for resource allocation in healthcare systems.
Methods
The study utilized a budget impact model (BIM) to evaluate costs associated with dostarlimab plus CP compared to existing treatment options. The analysis considered a three-year time horizon from 2026 to 2028. Inputs included epidemiological data, clinical outcomes, and cost/resource use associated with treatment regimens.
Results
The primary finding indicated a total cumulative budget impact of -$1,650,171 over three years. In the first year, the budget impact was -$326,607, and in the third year, it was -$668,830. The mean annual budget impact per patient treated with dostarlimab plus CP was reported as -$4,388.57.
Interpretation
The findings suggest that the introduction of dostarlimab plus CP could be budget neutral, with lower treatment acquisition costs compared to existing options. However, the effect size in terms of budget impact may not translate to clinical significance without data on treatment efficacy. Limitations include reliance on model estimates and the absence of direct clinical outcomes, which may affect the applicability of the results in practice.
Key findings
- 58 out of 250 eligible patients estimated to receive dostarlimab plus CP in the first year.
- 242 out of 569 eligible patients estimated to receive dostarlimab plus CP in the third year.
- -$326,607 annual budget impact in the first year.
- -$668,830 annual budget impact in the third year.
- -$1,650,171 total cumulative budget impact over three years.
- -$4,388.57 mean annual budget impact per patient treated with dostarlimab plus CP.
Limitations
- Model-based analysis without real-world data.
- No clinical efficacy or patient outcome data reported.
- Short time horizon of three years may not capture long-term effects.
- Sensitivity analysis conducted but details not provided.